News
FDA suspends muscular dystrophy drug
Digest more
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...
As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...
The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...
Duchenne Muscular Dystrophy affects 12,000 to 15,000 children and young adults in the United States and about 300,000 worldwide. It's caused by a mutation in the dystrophin gene, which makes a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback